Myriad Genetics (MYGN) issued an update on its FY13 earnings guidance on Monday morning. The company provided earnings per share guidance of $1.55-1.58 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.58. The company issued revenue guidance of $575-585 million, compared to the consensus revenue estimate of $583.30 million.
Myriad Genetics (MYGN) opened at 25.46 on Monday. Myriad Genetics (MYGN) has a 1-year low of $22.02 and a 1-year high of $31.80. The stock’s 50-day moving average is currently $26.15. The company has a market cap of $2.051 billion and a price-to-earnings ratio of 17.45.
Myriad Genetics last issued its quarterly earnings data on Tuesday, February 5th. The company reported $0.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.04. The company had revenue of $140.70 million for the quarter, compared to the consensus estimate of $143.71 million. During the same quarter last year, the company posted $0.33 earnings per share. Myriad Genetics’s revenue was up 19.6% compared to the same quarter last year. Myriad Genetics has set its FY13 guidance at $1.55-1.58 EPS. Analysts expect that Myriad Genetics (MYGN) will post $1.57 EPS for the current fiscal year.
A number of research firms have also recently commented on MYGN. Analysts at Zacks reiterated an outperform rating on shares of Myriad Genetics in a research note to investors on Tuesday, February 12th. They now have a $30.00 price target on the stock. On a related note, analysts at Cowen reiterated an outperform rating on shares of Myriad Genetics in a research note to investors on Wednesday, February 6th. Finally, analysts at Ladenburg Thalmann downgraded shares of Myriad Genetics from a buy rating to a neutral rating in a research note to investors on Tuesday, February 5th. They noted that the move was a valuation call.
Nine analysts have rated the stock with a buy rating, eight have given a hold rating, and one has issued a sell rating to the company’s stock. The stock currently has an average rating of overweight and an average target price of $30.45.
Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.